Biomerica (BMRA)
Makes rapid diagnostic tests and GI-focused laboratory assays for clinical and consumer use.
Something off on this page? Send us feedback.
Sells rapid and ELISA diagnostic tests, laboratory assays and consumer kits, with contract development and manufacturing alongside product sales. GI-focused inFoods and hp+detect add a laboratory-service pathway to a business manufactured in Irvine and Mexicali and distributed internationally.
Develops, manufactures and sells in-vitro diagnostic products spanning rapid and ELISA tests, laboratory assays, and consumer and point-of-care kits. The portfolio includes the inFoods IBS food-elimination assay, hp+detect H. pylori stool-antigen test, EZ Detect occult-blood test, and Aware breast self-exam pad.
Centers administration, regulatory work, product development, and primary manufacturing in Irvine, while Mexicali handles lower-cost assembly and manufacturing and BioEurope supports international distribution. Products reach clinical laboratories, health-care practices, retailers, e-commerce customers, and distributors; contract R&D and private-label manufacturing add a service revenue stream.
Relies increasingly on laboratory adoption and reimbursement for inFoods. Sales are geographically diversified but weighted outside North America, and ongoing operations depend on regulatory compliance, foreign distribution, supply continuity, and capital availability.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $1.3M · Total debt $1.9M · Total assets $6.8M · Shareholders' equity $2.6M
- Revenue
- $875.0K
- Operating income
- −$1.5M
- Net income
- −$1.1M
No dividends on record.
| Institutions | 4.05% | 125.2K shares | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 17.53% | 541.7K shares | |
| 8 holders · as of Aug 27, 2026 | |||
| Strategic holders | 14.89% | 460.1K shares | |
| 1 holder · as of Sep 10, 2026 | |||
| Other | 63.53% | 1.96M shares | |
| remainder | |||
3.09M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BRC Group Holdings, Inc.Strategic10 percent owner | 14.89% | 460,080 | filed Sep 10, 2026 |
Zackary S. IraniInsiderdirector, officer: Chief Executive Officer | 7.85% | 242,570 | filed Aug 27, 2026 |
Allen BarbieriInsiderdirector, officer: Executive Vice Chairman | 2.38% | 73,542 | filed Aug 27, 2026 |
Gary LuInsiderofficer: Chief Financial Officer | 1.92% | 59,375 | filed Dec 31, 2025 |
M. Huff GaryInsiderdirector | 1.66% | 51,250 | filed Aug 27, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Allen Barbieri | director, officer: Executive Vice Chairman | +20,000 | $1.60 |
| Aug 26, 2026 | Eric Chin | director | +6,250 | $1.60 |
| Aug 26, 2026 | David Moatazedi | director | +10,000 | $1.60 |
| Aug 20, 2026 | M. Huff Gary | director | +31,250 | $1.60 |
| Aug 26, 2026 | Zackary S. Irani | director, officer: Chief Executive Officer | +31,250 | $1.60 |
- Abbott
Broad clinical-lab and rapid diagnostics pressure.
- QuidelOrtho
Direct H. pylori stool-antigen testing overlap.
- Danaher
Large clinical-lab immunoassay and GI-testing incumbent.
- Ironwood Pharmaceuticals
IBS-C treatment competes for gastroenterology adoption.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Biomerica | $2.84 | +2.16% | $8.6M | — | — | 1.9 | −36.6% |
| Abbott | $103.64 | −0.09% | $179.49B | 33.4 | 17.9 | 3.9 | +13.0% |
| QuidelOrtho | $10.72 | −2.01% | $746.0M | — | 12.7 | 0.3 | +2.8% |
| Danaher | $221.67 | +0.26% | $155.44B | 39.3 | 25.0 | 6.2 | +5.5% |
| Ironwood Pharmaceuticals | $4.44 | −1.88% | $744.9M | 5.9 | 3.6 | 1.9 | +32.6% |
| Median | 33.4 | 15.3 | 2.9 | +9.3% |